Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review.

@article{Travadi2003PhosphodiesteraseIF,
  title={Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review.},
  author={Javeed N Travadi and Sanjay K. Patole},
  journal={Pediatric pulmonology},
  year={2003},
  volume={36 6},
  pages={529-35}
}
Persistent pulmonary hypertension of the newborn (PPHN) is a complex syndrome with multiple causes, with an incidence of 0.43-6.8/1,000 live births and a mortality of 10-20%. Survivors have high morbidity in the forms of neurodevelopmental and audiological impairment, cognitive delays, hearing loss, and a high rate of rehospitalization. The optimal approach to the management of PPHN remains controversial. Inhaled nitric oxide (iNO) is currently regarded as the gold standard therapy, but with as… CONTINUE READING